High Health Care Utilization, Poor Survival Seen for Over 70s With AML
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 19, 2024 -- Older patients with acute myeloid leukemia (AML) have high health care utilization and poor survival outcomes, according to a study published online Aug. 13 in Hematological Oncology.
Marie Anne-Catherine Neumann, Ph.D., from the University of Cologne in Germany, and colleagues conducted an analysis of 107 consecutive patients with newly diagnosed AML aged 70 years and older treated at an academic tertiary care center in Germany to examine characteristics, outcomes, and health care utilization.
The researchers found that 35, 55, and 10 percent of patients received intensive induction chemotherapy, low-intensity treatment, and either did not receive AML-directed treatment or follow-up ended before initiation of treatment, respectively. Forty-seven percent of patients had at least one intensive care unit admission; specialized palliative care was involved in 43 percent of cases. Overall median survival was 2.5 months, and the rate of one-year overall survival was 16 percent. The median proportion of time spent in the hospital between AML diagnosis and death was 56 percent among patients who died during observation. Normal wards and the intensive care unit were the most common places of death (31 and 28 percent, respectively); death occurred less often in a palliative care unit or at home (14 and 12 percent, respectively).
"The present analysis highlights poor survival outcomes on the one hand and extensive health care utilization on the other hand in patients with AML aged 70 years or older," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Rebound Weight Gain Common After Discontinuing Antiobesity Medications
FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published...
Patients Face High Out-of-Pocket Costs After Incident Cancer Diagnosis
FRIDAY, July 25, 2025 -- Patients face high out-of-pocket costs (OOPCs) after an incident diagnosis of cancer, with costs increasing with stage of diagnosis, according to a study...
Exposure to PFAS Mixtures Linked to Increased Odds of Type 2 Diabetes
FRIDAY, July 25, 2025 -- In multiethnic populations, exposure to per- and polyfluoroalkyl substance (PFAS) mixtures may be associated with increased odds of type 2 diabetes (T2D)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.